| Background: TAS-102 has been applied to metastatic colorectal cancer(mCRC)patients who had received at least two prior regimens of standard chemotherapy.This meta-analysis is designed to assess the efficacy and safety of TAS-102 in mCRC.Methods: We searched randomized controlled trials(RCTs)through PubMed,EMBASE,Web of Science,Cochrane clinical trials databases and clinicaltrial.gov from database initiation to March 2018.The overall survival(OS),progression-free survival(PFS),disease control rate(DCR)and the incidence of adverse events were summarized with the use of hazard ratio(HR)or risk ratio(RR).Results: Three RCTs with 1318 patients were included.Results showed that TAS-102 significantly improved OS(HR 0.70,95% CI0.62-0.79)and PFS(HR 0.46,95% CI 0.40-0.52).The pooled odds ratio(OR)of DCR was 4.15(95% CI 3.18-5.43).Notably,there were significant OS benefits both in patients with KRAS mutation(HR 0.76,95% CI0.63-0.92)and KRAS wild-type(HR 0.66,95% CI 0.55-0.79).The mostcommon toxicities associated with TAS-102 were neutropenia(RR 116.51,95% CI 23.51-577.33),leucopenia(RR 67.70,95% CI 13.63-336.29),anaemia(RR 4.28,95% CI 2.70-6.79)and diarrhea(RR 5.10,95% CI1.40-18.61).Conclusions: TAS-102 significantly improves OS,PFS and DCR in patients with mCRC with tolerable toxicity.Meanwhile,the OS benefits have nothing to do with KRAS status. |
PDF Full Text Request